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Abstract: Lumiracoxib is a COX2 inhibitor that is highly selective, is more effective than 
placebo on pain in osteoarthritis (OA), with similar analgesic and anti-inﬂ  ammatory effects as 
non-selective NSAIDs and the selective COX2 inhibitor celecoxib, has a lower incidence of 
upper gastrointestinal (GI) side effects in patients not taking aspirin, and a similar incidence 
of cardiovascular (CV) side effects compared to naproxen or ibuprofen. In the context of 
earlier guidelines and taking into account the GI and CV safety results of the TARGET study, 
lumiracoxib had secured European Medicines Agency (EMEA) approval with as indication 
symptomatic treatment of OA as well as short-term management of acute pain associated 
with primary dysmenorrhea and following orthopedic or dental surgery. In the complex 
clinical context of efﬁ  ciency and safety of selective and non-selective COX inhibitors, its 
prescription and use should be based on the risk and safety proﬁ  le of the patient. In addition, 
there is further need for long-term GI and CV safety studies and general post-marketing 
safety on its use in daily practice. Meanwhile, at the time of submission of this manuscript, 
the EMEA has withdrawn lumiracoxib throughout Europe because of the risk of serious side 
effects affecting the liver.
Keywords: lumiracoxib, NSAIDs, COX2 inhibitors, gastro-intestinal and cardiovascular 
safety
Introduction
Non-selective non-steroidal anti-inﬂ  ammatory drugs (NSAIDs) are widely used by 
patients with acute pain or with chronic pain due to osteoarthritis (OA) and rheuma-
toid arthritis (RA) (ACR Recommendations 2000; Hochberg 2002; Jordan et al 2003; 
Schnitzer 2006). They put them at increased risk for clinically important damage to 
the mucosa of the upper part of the gastrointestinal tract (Wolfe et al 1999), with a 
relative risk (RR) of 2.7–5.4 for the so-called PUBs and POBs (PUBs: Perforation, 
clinically manifest Ulcer and Bleeding; POBs: Perforation, Obstruction, Bleeding) 
(Hernandez-Diaz and Rodriguez 2000; Ofman et al 2002). OA and RA patients were 
found to be 2.5–5.5 times more hospitalized for NSAID-related gastro-intestinal 
(GI) events than the general population (Singh 1988) and 5%–10% of PUBs are fatal 
(Armstrong and Blower 1987).
Cyclo-oxygenase 2 (COX2)-selective inhibitors have been developed based on the 
ﬁ  nding that the COXs that are constitutively involved in the physiology of the GI mucosa 
(COX1) are different from the ones that are inducible by inﬂ  ammation (COX2) (Vane 
et al 1994; Warner et al 1999; Fitzgerald 2003). Therefore, selective inhibition of COX2 
could dissociate anti-inﬂ  ammatory activity from GI side effects. In this way, COX2 
selective inhibitors should reduce clinically manifest ulcers and ulcer complications 
compared with non-selective NSAIDs, meanwhile exerting similar effects on acute pain Therapeutics and Clinical Risk Management 2008:4(2) 338
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(eg, primary dysmenorrhea and following orthopedic or dental 
surgery) and chronic pain in patients with OA or RA.
Preclinical in vitro and animal studies using have been 
performed proving that COX2 selectivity is a promising 
approach (Vane et al 1994; Warner et al 1999; Fitzgerald 
2003). Several endoscopic studies with selective COX2 
inhibitors in humans have shown a reduction of the occur-
rence of upper GI lesions compared to non-selective NSAIDs 
(James and Hawkey 2003); moreover, it has been shown that 
the endoscopic ulcer rate in healthy volunteers or in patients 
with osteoarthritis was not different between COX2 inhibitor-
users and placebo (Laine et al 1999; Rordorf et al 2003a).
However, endoscopic lesions have been considered only 
as an indicator and surrogate endpoint for clinical upper GI 
safety (Goldkind 2000). Therefore, clinical trials have been 
performed to study the effect of selective COX2 inhibitors 
on clinical relevant upper GI events. Since clinically manifest 
ulcers and ulcer complications are relatively scarce, very 
large studies (with a high number of patients) have been 
performed to show differences in PUBs and POBs.
During the course of emerging studies, it became clear 
that selective COX2 inhibitors could be associated with 
an increased incidence of cardiovascular (CV) thrombotic 
events, including stroke and particularly myocardial infarc-
tion (MI), as demonstrated in the VIGOR study, in which the 
risk of MI was higher in RA-patients treated with rofecoxib 
than in naproxen users (Bombardier et al 2000). At that time, 
it was debated whether this difference in CV risk was the 
result of a protective effect of naproxen on the incidence of 
MI (Bombardier et al 2000), or a consequence (side-effect) 
of the use of COX2 inhibitors.
Later on, in studies developed to observe whether the 
use of COX2 inhibitors protected against the occurrence 
of colonic polyps, it has become clear that rofecoxib, as 
compared to placebo, doubles the risk for thrombotic events, 
mainly myocardial infarction and ischemic CV events 
(Bresalier et al 2005; Kerr et al 2007). Also for other COX2 
inhibitors, celecoxib and valdecoxib, an elevated CV risk has 
been shown (Nussmeier et al 2005; Solomon et al 2005).
Although the exact mechanism of this association is still 
unclear, the balance between prostacyclin (PGI2) and throm-
boxane A2 (TXA2) is presumably shifted to an increased risk 
for thrombo-embolic events (Fitzgerald 2003). It has been 
suggested that COX2 is up regulated in vascular segments 
under conditions of increased vascular shear stress, and that 
the reduction of endovascular production of prostacyclin 
by the use of COX2 inhibitors induces an elevated risk of 
vascular thrombotic events (Solomon 2005).
Besides an elevated CV risk, it has recently been 
shown that the use of conventional NSAIDs is associated 
with edema, congestive heart failure, cardiac arrhythmias, 
and an increased risk of CV events (Kearney et al 2006; 
McGettigan and Henry 2006; Vonkemann et al 2006; Zhang 
et al 2006).
In this context, it was realised that the development of 
new selective COX2 inhibitors had to be evaluated in a much 
broader context of safety than only GI protection and had to 
include data on CV safety (Silverstein et al 2000; Farkouh 
et al 2004; Schnitzer et al 2004; Cannon et al 2006; Laine 
et al 2007). In order to perform such studies, larger trials 
were needed with more endpoints than in the original stud-
ies that focused on GI protection only. In addition, also for 
the non-selective NSAIDs additional data were required to 
adequately judge their effect on CV risk.
Several clinical trials have been performed to study both 
the GI and CV safety with COX2 (Tables 1–4), including 
VIGOR (rofecoxib vs naproxen) (Bombardier et al 2000), 
CLASS (celecoxib vs diclofenac and ibuprofen) (Silverstein 
et al 2000), MEDAL (etoricoxib vs diclofenac in a pooled 
analysis) (Cannon et al 2006; Laine et al 2007), and TAR-
GET (lumiracoxib vs ibuprofen and naproxen) (Farkouh 
et al 2004; Schnitzer et al 2004), which will be discussed in 
detail later in this review.
These studies differed between each other in many 
aspects. Differences included indications for treatment (OA 
and/or RA), number of patients included (between 8059 and 
37,701), the comparator non-selective NSAIDs (naproxen, 
diclofenac, ibuprofen; none was placebo-controlled), dura-
tion of the study (6–36 months), exclusion or not because 
of history of GI risks/events (GI surgery, current bleeding, 
active GI disorder, recent ulcer, intake of GI protectors, 
bleeding last year, any perforation, obstruction or not), GI 
protection during the study (not allowed, allowed, stimulated 
in high risk patients), deﬁ  nitions of upper GI side effect end-
points (various combinations of PUBOs, eventually further 
speciﬁ  ed as complicated or not), exclusion or not because 
of history of CV risks/events (during variable time periods 
before the study (during last 6 months to ever), and deﬁ  ned 
as any CV event or speciﬁ  ed as MI (clinical or on ECG), 
coronary bypass, percutaneous coronary intervention, stroke, 
new angina, low dose aspirin (allowed, stimulated, or not 
allowed), severe heart failure), and deﬁ  nitions of CV side 
effect endpoints (MI alone, composite endpoints including 
variable combinations of MI, stroke, angina, any or arterial 
thrombotic events, or including more standardized outcomes 
from the Anti-Platelet Trialists’ Collaboration endpoint).Therapeutics and Clinical Risk Management 2008:4(2) 339
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In these studies, rofecoxib and etoricoxib decreased the 
risk of GI event endpoints (Table 2), but the size and sig-
niﬁ  cance of effects according to deﬁ  nitions of GI events and 
reporting on signiﬁ  cance of interaction of treatment-by-sub-
group analysis differed between the drugs (Bombardier et al 
2000; Silverstein et al 2000; Cannon et al 2006; Laine et al 
2007). Celecoxib did not decrease the primary GI endpointv 
(POBs) over the entire duration of the study, but signiﬁ  cantly 
reduced the risk of GI events when symptomatic ulcers were 
included in the analysis (Silverstein et al 2000).
In these studies, rofecoxib increased the risk of MI (HR: 
4.25, CI: 1.39–17.37) (Bombardier et al 2000), which was the 
reason for withdrawal of rofecoxib (Vioxx®) from the market 
in September 2004. Low dose celecoxib and etoricoxib did 
not affect the risk of pre-speciﬁ  ed composite CV endpoints 
in the total group of patients and in speciﬁ  ed subgroups (on 
low dose aspirin or not) as compared to their comparator 
non-selective NSAID(s) (Table 3) (Silverstein et al 2000; 
Cannon et al 2006; Laine et al 2007).
It is important to realize that the similarity of incidence of 
CV risk between selective and non-selective COX inhibitors 
does not mean that there is no increased CV risk of selective 
COX2 inhibitors compared to placebo. On the contrary, com-
pared to placebo, it has been demonstrated that the selective 
COX2 inhibitors rofecoxib (Bresalier et al 2005; Kerr et al 
2007) and celecoxib (Solomon et al 2005) at high doses 
increase the risk of CV events compared to placebo. Fur-
thermore, non-selective NSAIDs, such as ibuprofen (Antman 
et al 2007), diclofenac (Antman et al 2007), but probably not 
naproxen (Antman et al 2007) and even paracetamol (Chan 
et al 2006), were associated with an increased risk for CV 
events compared to placebo in meta-analyses.
In this complex safety context, we review here the data 
on the effects and safety of lumiracoxib, a highly selective 
COX2 inhibitor.
Lumiracoxib
Preclinical data
Lumiracoxib (Prexige®) is a selective COX2 inhibitor 
developed for the treatment of osteoarthritis, rheumatoid 
arthritis, and acute pain (Lyseng-Williamson and Curran 
2004; Esser et al 2005).
Lumiracoxib differs structurally from other drugs in the 
class of selective COX2 inhibitors (Brune and Hinz 2004; 
Mangold et al 2004). The other inhibitors contain a tricyclic 
ring and a sulfone or sulfonamide group (Brune and Hinz 
2004) whereas lumiracoxib is a phenyl acetic acid derivative. 
It has the highest selectivity (selective for COX2 compared 
with COX1 in the human whole blood assay with a ratio of 
515:1 in healthy subjects and in patients with osteoarthritis 
or rheumatoid arthritis) and a fairly short plasma half-life 
(3–6 hours) compared with other COX2-selective inhibitors 
(Esser et al 2005).
Lumiracoxib has good oral bioavailability (74%). It is 
rapidly absorbed, reaching maximum plasma concentrations 
2 hours after dosing, and is highly plasma protein bound. 
Lumiracoxib has a short elimination half-life from plasma 
(mean 4 hours) and demonstrates dose-proportional plasma 
Table 1 General description of main large-scale safety trials with selective COX2 inhibitors and description of patients excluded 
from participating in the studies
Drug (reference) Study Diagnoses and 
patients (n)
Duration 
(months)
Comparator 
drug
Risk patients excluded 
GI history
CV history
Rofecoxib 
(Bombardier 2000)
VIGOR RA (8 076) 12 Naproxen GI surgery, current B, IBD, 
previous or current PPI
History of CV last 2 yrs, MI or 
coronary bypass last yr, previous 
or current aspirin
Celecoxib 
(Silverstein 2000)
CLASS OA, RA (8 059) 6 Ibuprofen, 
diclofenacv
Active GI, U last 30 d, any 
GI surgery
No exclusion criteria
Etoricoxib 
(Cannon 2006; 
Laine 2007)
MEDAL OA, RA (37 701) 36 Diclofenac No exclusion
PPI or misoprostol rec-
ommended if at GI risk
MI or coronary bypass or 
percutaneous coronary 
intervention during last 6 mo,
aspirin recommended if at CV risk
Lumiracoxib 
(Schnitzer 2004; 
Farkouh 2004)
TARGET OA (18 325) 12 Ibuprofen, 
naproxen
On GI protection, U last 
3 mo, B last yr, any P or O
MI (clinical, on ECG), stroke, 
coronary bypass graft surgery, 
new angina during last 6 mo, high 
CV risk without aspirin, severe 
heart failure, on anticoagulation 
therapy
Abbreviations: B, bleeding; CV, cardiovascular; GI, gastrointestinal; IBD, inﬂ  ammatory bowel disease; MI, myocardial infarction; O, obstruction; OA, osteoarthritis; P, perfora-
tion; RA, rheumatoid arthritis; PPI, proton pump inhibitors; U, ulcer.Therapeutics and Clinical Risk Management 2008:4(2) 340
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pharmacokinetics with no accumulation during multiple 
dosing.
Lumiracoxib is metabolized extensively prior to excre-
tion, with only a small amount excreted unchanged in urine or 
feces. Lumiracoxib and its metabolites are excreted via renal 
and fecal routes in approximately equal amounts (Lyseng-
Williamson and Curran 2004).
Lumiracoxib does not exhibit any clinically meaningful 
interactions with a range of commonly used medications 
including aspirin (acetylsalicylic acid), fluconazole, an 
ethinylestradiol- and levonorgestrel-containing oral contra-
ceptive, omeprazole, the antacid Maalox®, methotrexate, and 
warfarin (although, as in common practice, routine monitor-
ing of coagulation is recommended when lumiracoxib is 
co-administered with warfarin) (Lyseng-Williamson and 
Curran 2004).
Clinical efﬁ  cacy
The effectiveness of lumiracoxib was superior to placebo 
in patients with OA at doses of 100 mg and 200 mg once 
daily and similar to celecoxib and non-selective NSAID, as 
described and reviewed in detail in Lyseng-Williamson and 
Curran (2004).
Several studies have been shown the superiority of 
lumiracoxib compared to placebo in pain in RA (Guesens 
et al 2004), after surgery, orthopedic surgery, primary dys-
menorrhea and tension headache (Lyseng-Williamson and 
Curran 2004).
Safety
Upper gastrointestinal safety: endoscopic studies
In endoscopic studies, lumiracoxib has been associated with 
a rate of acute gastric injury and chronic ulcer formation 
that does not differ from placebo (Rordorf et al 2003b) and 
which was signiﬁ  cantly lower than with the non-selective 
NSAID ibuprofen and with celecoxib (Hawkey et al 2004; 
Kivitz et al 2004).
Clinical gastrointestinal safety
To establish the gastrointestinal safety of lumiracoxib, the 
Therapeutic Arthritis Research and Gastrointestinal Event 
Trial (TARGET) was performed to test the hypothesis that 
patients with osteoarthritis, randomized to lumiracoxib 
(400 mg once daily, which is 2–4 times the recommended 
dose for osteoarthritis), had signiﬁ  cantly fewer compli-
cated ulcers than patients randomized to either ibuprofen 
Table 2 Gastrointestinal endpoints in studies of selective COX2 inhibitors
Drug 
(reference)
Study GI protection 
allowed in study
GI endpoints Hazard ratios, relative risks (RR) or incidence (%) of 
upper GI risk endpoints
All No aspirin On aspirin
Rofecoxib 
(Bombardier 
2000)
VIGOR Yes Conﬁ  rmed POBU 0.5 (0.3−0.6)v Idem Excluded
Complicated GI 
(POB)
0.4 (0.2−0.8) Idem Excluded
Celecoxib 
(Silverstein 
2000)
CLASS No POB RR: 0.53 (0.26−1.11) RR: 0.35 (0.14−0.98) 1.0% vs 2.1, NS
Symptomatic U + 
POB
RR: 0.59 (0.38−0.94) RR: 0.48 (0.28−0.89) 4.7% vs 6.0%, NS
Etoricoxib 
(Cannon 2006; 
Laine 2007)
MEDAL Yes Clinical POBUa All 0.69 (0.57−0.83) 0.60 (0.45−0.80) 0.78 (0.60−1.01)
No PPI 0.62 (0.45−0.83) 0.60 (0.43−0.86) 0.93 (0.65−1.35)
+ PPI 0.74 (0.58−0.95) 0.59 (0.36−0.98) 0.64 (0.44−0.93)
Complicated GI 
(POB)a
All 0.91 (0.67−1.24) 0.90 (0.53−1.50) 0.93 (0.63−1.36)
No PPI 1.03 (0.70−1.52) 0.96 (0.52−1.79) 1.09 (0.66−1.77)
+ PPI 0.72 (0.42−1.22) 0.77 (0.30−1.95) 0.70 (0.37−1.34)
Uncomplicated Ua All 0.57 (0.45−0.74) 0.50 (0.35−0.71) 0.67 (0.47−0.96)
No PPI 0.58 (0.41−0.81) 0.49 (0.32−0.75) 0.77 (0.44−1.34)
+ PPI 0.57 (0.39−0.83) 0.53 (0.29−0.98) 0.61 (0.38−0.97)
Lumiracoxib 
(Schnitzer 2004; 
Farkouh 2004)
TARGET No Deﬁ  nite or probable complicated
U (POB)
vs ibuprofen + 
naproxen
0.34 (0.22−0.52) 0.21 (0.12−0.37) 0.79 (0.40−1.55)
vs ibuprofen 0.29 (0.14−0.59) 0.17 (0.07−0.45) 0.92 (0.27−3.20)
vs naproxen 0.37 (0.22−0.63) 0.24 (0.12−0.50) 0.73 (0.32−1.65)
aNo treatment-by-subgroup interaction.
Abbreviations: B, bleeding; GI, gastrointestinal; O, obstruction; P, perforation; PPI, proton pump inhibitors; U, ulcer.Therapeutics and Clinical Risk Management 2008:4(2) 341
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(3 × 800 mg/day) or naproxen (2 × 500 mg/day), without 
affecting CV risk (Farkouh et al 2004; Schnitzer et al 2004). 
To address these issues, TARGET (n = 18,325) was, by 
design, much larger than CLASS (n = 8059) and VIGOR 
(n = 8 076) outcome trials, but smaller than the pooled 
analysis in MEDAL (n = 37,701).
The TARGET trial included patients with clinical OA 
of hip, knee or hands, or with radiographic OA of the spine 
(without of radicular symptoms). Based on the GI risk pro-
ﬁ  le at baseline, patients were excluded if they were on GI 
protection, had an upper GI ulcer during the last 3 months, 
GI bleeding last year or any history of perforation or 
obstruction (Table 1) (Schnitzer et al 2004). Lumiracoxib 
showed, in the total group, a 3- to 4-fold reduction in upper 
GI ulcer complications (POBs) compared both comparators 
combined (RR: 0.34, CI: 0.22–0.52) and either naproxen or 
ibuprofen (Table 2). Remarkably, the relative risk reduc-
tion for lumiracoxib (0.34) seems at ﬁ  rst sight to be larger 
than for rofecoxib, celecoxib, and etoricoxib. However, this 
comparison is difﬁ  cult, if not impossible to interpret, since it 
is not based on a head to head comparison, and the inclusion 
and exclusion criteria and deﬁ  nition of endpoints of these 
studies were different. This effect was found in patients not 
taking low dose aspirin (RR: 0.21, CI: 0.12–0.37), but was 
not signiﬁ  cant in those taking low dose aspirin (RR: 0.79, 
CI: 0.40–1.55).
Clinical cardiovascular safety
Based on CV risk proﬁ  le at baseline, patients were excluded 
from the TARGET study if they had a history of MI (clinical 
or silent as shown on ECG), stroke, coronary bypass, new 
angina of recent onset (last 6 months), high CV risk without 
intake of aspirin or severe heart failure (Farkouh et al 2004). 
The primary composite endpoint (the incidence of MI, stroke, 
and CV death) did not differ between lumiracoxib and 
ibuprofen or naproxen combined (RR: 1.14, CI: 0.78–1.66) 
or separately, irrespective of aspirin use (RR: 1.22 and 1.04). 
Thus, the overall CV signal showed no difference but this is 
because the study is underpowered to demonstrate statistically 
signiﬁ  cant and clinically meaningful differences. There was 
a trend towards more CV events relative to naproxen (RR: 
1.46, CI: 0.89–2.37) and fewer events relative to ibuprofen 
(RR: 0.76, CI: 0.41–1.40).
It is important to realize that the TARGET trial has been 
performed in patients with a relatively low risk for CV events. 
Patients were excluded from the study if they had a MI, 
stroke, coronary artery bypass graft surgery, percutaneous 
coronary intervention or new-onset angina within 6 months 
prior to screening, electrocardiogram (ECG) evidence of 
silent myocardial ischemia, New York Heart Association 
congestive heart failure class III–IV, or if they were receiv-
ing anticoagulation therapy. As a consequence, it cannot be 
fully excluded that a difference between the comparators 
Table 3 Cardiovascular endpoints in studies of selective COX2 inhibitors
Drug (reference) Study Aspirin 
allowed
CV endpoints Hazard ratios or incidence of CV endpoints
All No aspirin On aspirin
Rofecoxib 
(Bombardier 2000)
VIGOR No MI 4.25 (1.39−17.37) Idem Excluded
CV death c0.2% vs 0.2%, NS Idem Excluded
Celecoxib 
(Silverstein 2000)
CLASS Yes MI, stroke or angina 0.9% vs 1.0%, NS 0.5% vs 0.4%, NS nr
Etoricoxib (Cannon 
2006; Laine 2007)
MEDAL Stimulated aAny thrombotic events 0.95 (0.81−1.11)
d1.0% vs 1.0%, NS d1.67% vs 1.87%, NS
aArterial thrombotic events 0.96 (0.81−1.13) nr nr
a,bAPTC (all MI, stroke or vascular death) 0.96 (0.79−1.16) nr nr
Lumiracoxib 
(Schnitzer 2004; 
Farkouh 2004)
TARGET Yes bAPTC (all MI, stroke or vascular death)
  vs  ibuprofen  + naproxen 1.14 (0.78−1.66) 1.22 (0.74−2.02) 1.04 (0.59−1.84)
  vs  ibuprofen 0.76 (0.41−1.40) 0.94 (0.44−2.04) 0.56 (0.20−1.54)
  vs  naproxen 1.46 (0.89−2.37) 1.49 (0.76−2.92) 1.42 (0.70−2.90)
Conﬁ  rmed or probable MI (clinical and
silent)
  vs  ibuprofen  + naproxen 1.31 (0.70−2.45) 1.47 (0.63−3.39) 1.14 (0.44−2.95)
  vs  ibuprofen 0.66 (0.21−2.09) 0.75 (0.20−2.79) 0.47 (0.04−5.14)
  vs  naproxen 1.77 (0.82−3.84) 2.37 (0.74−7.55) 1.36 (0.47−3.93)
aPer-protocol analysis, similar results after ITT analysis.
bAPTC, Anti-Platelet Trialists’ Collaboration endpoint.
cincidence.
devents per 100 patient yrs.
Abbreviation: nr, not reported.Therapeutics and Clinical Risk Management 2008:4(2) 342
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would have been observed if more high risk patients would 
have been enrolled.
The incidence of composite GI and CV endpoints 
combined fell by 35% in patients treated with lumiracoxib 
compared to both comparators (RR: 0.65, CI: 0.49–0.84), by 
50% compared to ibuprofen (p   0.01) and by 25% compared 
to naproxen (NS).
Other safety data
Non-selective NSAIDs interfere with COX1 and COX2 in 
the kidney (Harris 2006). Their most common renal side 
effect is peripheral edema due to increased sodium retention 
(Harris 2006), which also is one of the contributors to an 
increase in blood pressure. Acute renal failure is a rare but 
potentially serious complication of non-selective NSAIDs 
(Harris 2006), which predominantly occurs in elderly with 
cardiovascular involvement during periods of dehydration 
(diarrhea, high fever). Also selective COX2 inhibitors may 
cause edema, congestive heart failure and modest elevations 
of blood pressure (Harris 2006). In the MEDAL study, more 
discontinuations were observed in etoricoxib users due to 
hypertension and edema than in diclofenac users (no differ-
ence was found for congestive heart failure) (Cannon et al 
2006; Laine et al 2007).
In the TARGET study (Farkouh et al 2004; Schnitzer et al 
2004), the incidence of major renal events and chronic heart 
failure were similar between the treatment groups (Table 4), 
while unfortunately the incidence of peripheral edema was 
not reported. Interestingly, blood pressure remained stable 
in patients treated with lumiracoxib, which was signiﬁ  cantly 
different from the moderate but signiﬁ  cant increase in blood 
pressure with naproxen and diclofenac. In the TARGET study 
no data were presented on cutaneous side effects (Farkouh 
et al 2004; Schnitzer et al 2004).
Hepatotoxicity has been the reason for withdrawal of some 
NSAIDs from the market, but symptomatic hepatic effects 
attributable to NSAIDs are rare and usually mild (Bannwarth 
and Berenbaum 2005). Lumiracoxib has a molecular phenyl 
acetic acid structure that is similar to that of diclofenac, the 
most widely prescribed NSAID world-wide, probably with an 
elevated risk for hepatotoxicity (which is estimated to occur in 
4% of all patients). In the TARGET study the incidence of seri-
ous liver abnormalities (not further speciﬁ  ed in the manuscript) 
was similar between the treatment groups, but lumiracoxib was 
associated with a RR of 3.97 (CI: 2.96–5.32) for increase in liver 
tests above 3 times the upper normal limit (Farkouh et al 2004; 
Schnitzer et al 2004). Thus, the risk of hepatotoxicity with the 
use of lumiracoxib is higher than for naproxen and ibuprofen. 
At the time of ﬁ  rst submission of this manuscript, lumiracoxib 
was withdrawn from the market in Australia (where it had 
been on the market for several years and prescribed to 60,000 
patients in doses up to 400 mg/day) because of 8 reports of 
serious liver adverse reactions to the drug, including 2 deaths 
and 2 liver transplants, further details of which were not yet 
available. Meanwhile, due to these serious liver adverse affects 
at doses  100 mg/day, lumiracoxib was withdrawn from the 
market in several countries, including the UK and Germany. 
In this context lumiracoxib should, were available, be limited 
to the lowest effective dose for the shortest possible duration of 
treatment. The reader is advised to inspect the safety issues that 
Table 4 Incidence of other side effects in studies of selective COX2 inhibitors
Study
(reference)
Drugs Side effects 
Renal Edema Blood pressure Hypertension CHF Hepatic Cutaneous
Creat+v systolic diastolic ALT+AST+ reactions
VIGOR 
(Bombardier 2000)
Rofecoxib 1.2% nr nr nr nr nr nr nr
Naproxen 0.9%
CLASS 
(Silverstein 2000)
Celecoxib 0.7%* 2.8% nr nr 1.7%* nr 0.6%* 7.5%*
Diclofenac 1.2% 3.5% 2.3% 2.3% 4.1%
MEDAL 
(Cannon 2006;
Laine 2007)
Etoricoxib 0.4%–2.3% 0.8%–1.9% 
(**at 90 mg)
nr nr 2.2%–2.5% ** 0.1%–0.7% 0.3%–0.4% ** nr
Diclofenac 0.4 to 1.8% 0.4%–0.8% 0.7%–1.6% 0.1%–0.3% 1.5%–5.0%
TARGET
(Schnitzer 2004;
Farkouh 2004)
Lumiracoxib ***0.51% nr +0.4 mm§ –0.1 mm§ nr 0.24% 0.07%$$ 2.57%$$$ nr
Naproxen/
Diclofenac
0.37% +2.1 mm +0.5 mm 0.34% 0.03% 0.63%
*p   0.05, §p   0.0001 vs control drug.
**p   0.05 for discontinuations between treatment groups.
***major renal events, NS.
$$serious liver abnormalities (not further speciﬁ  ed), NS.
$$$transaminases  × 3 times upper normal limit, p   0.0001.
Abbreviations: ALT+, elevated alanine aminotransferase;   AST+, elevated aspartate aminotransferase; CHF, cardiac heart failure; nr, not reported.Therapeutics and Clinical Risk Management 2008:4(2) 343
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are emerging about liver safety, including baseline evaluation 
of history of liver diseases and regular checking liver function 
during treatment, and instructions about follow-up of liver 
function tests during treatment.
Conclusions
Lumiracoxib is a COX2 inhibitor that is highly selective, 
is more effective than placebo on pain in OA, with similar 
analgesic and anti-inﬂ  ammatory effects as non-selective 
NSAIDs and the selective COX2 inhibitor celecoxib, has 
a lower incidence of upper GI side effects in patients not 
taking aspirin and a similar incidence of CV side effects as 
compared to naproxen or ibuprofen.
In the context of earlier guidelines (ACR Recommendations 
2000; Hochberg 2002; Jordan et al 2003; Schnitzer 2006) and 
taking into account the GI and CV safety results of the TAR-
GET study (Farkouh et al 2004; Schnitzer et al 2004), lumira-
coxib is strictu sensu indicated in the treatment of patients with 
clinical OA of hip, knee or hands, or with radiographic OA of 
the spine, who do not respond to conventional treatment (such 
as analgesics [acetaminophen], physical therapy, and weight 
reduction in case of hip and knee OA), who have a moderate 
or high GI risk (with the restriction that in the TARGET study 
patients with a recent ulcer or bleeding or any history of per-
foration or obstruction were excluded) and a low CV risk and 
are not taking low dose aspirin (Table 5) (Chan 2006).
Lumiracoxib has been secured EMEA approval under 
the name of Prexige™ and Prexigen™ and has been launched 
in the UK since January 2006, where it is indicated for 
symptomatic treatment of osteoarthritis as well as short-
term management of acute pain associated with primary 
dysmenorrhea and following orthopedic or dental surgery 
(www.emea.eu). The UK acted as the reference state in the 
EU’s mutual recognition procedure.
In the complex clinical context of efﬁ  ciency and safety of 
selective and non-selective COX inhibitors, the prescription 
and use of COX2 inhibitors should be based on the risk and 
safety proﬁ  le of the patient. One example is given in Table 5, 
in which the use of selective COX2 is proposed to be limited 
to patients with a low CV risk together with a moderate or 
high GI risk (Chan 2006). In addition, there is further need 
for long-term GI and CV safety studies on the use of selective 
and non-selective COX inhibitors. In view of the liver adverse 
effects, lumiracoxib should be limited to the lowest effective 
dose for the shortest possible duration of treatment, with 
special attention for liver toxicity according to the upcom-
ing safety instructions. However, at the time of submission, 
lumiracoxib had been withdrawn from the market in several 
countries, including the UK and Germany, because of liver 
side effects at doses  100 mg/day. Meanwhile, at the time 
of proof approval of this paper, the European Medicines 
Agency (EMEA) had completed a review of the safety of 
medicines containing lumiracoxib. The Agency’s Committee 
for Medicinal Products for Human Use (CHMP) concluded 
that the beneﬁ  ts of these medicines no longer outweigh their 
risks, and that all marketing authorizations should be with-
drawn throughout Europe because of the risk of serious side 
effects affecting the liver (www.emea.europa.eu).
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